With a median progression-free survival nearing four years in ROS1 lung cancer, Nuvation Bio’s breakthrough therapy signals a turning point for precision oncology - validating Dr. David Hung’s patient-first vision.
September’s FDA approvals signaled shifting rules in biopharma - faster launches, smarter formulations, and bold plays from rising innovators and the familiar giants.
Backed by $70 million in Series A funding, Excellergy emerges from stealth with a mission to lead a new era in immunology - targeting the full IgE pathway to redefine how allergic diseases are treated.
“Fifteen to twenty years ago, a woman under 35 had a 20% chance of live birth per IVF cycle. At Kindbody, today, it’s greater than 50%,” David Stern credits lab innovation and AI for rewriting fertility’s odds.
“After just one single infusion, about a third of patients remained in remission for five years. Some physicians even called it a functional cure,” Ying Huang underlines why CARVYKTI is reshaping expectations in oncology.
"Some companies can’t even finish clinical trials because they can’t get enough material. It all comes down to the supply chain,” Thomas Eiden underscores why secure isotope access is critical for next-generation cancer treatment.
“Around 80 percent of payments in agriculture are still paper checks. We’re literally burning gasoline to move paper,” Jake Joraanstad calls out the analog inefficiencies undermining agriculture’s bottom line.
"Reducing our own footprint matters greatly, but the biggest point of impact is what our products can do; how they enhance sustainability when our customers use them; or when consumers use the products that our ingredients go into.”
"I can tell Starbucks the exact number of their containers that came through - down to whether they came from a resident or a commercial business,” Tim Stuart shows how AMP’s AI turns data on trash into corporate sustainability insights.
"Nickel stays nickel, lithium stays lithium. If you recycle down to the elemental level, you can build them back up again and again - indefinitely,” Ryan Melsert reveals why elemental recovery is the foundation for a resilient battery supply chain.
"Second-hand in the U.S., and globally, is projected to nearly double by 2030. The short answer is that the world needs more resale,” ThredUp's James Reinhart reveals how partnerships, tech, and trust are fueling the recommerce boom.
"Anybody can be a shipowner if they can raise the capital. What sets you apart is the organization you build around the ships,” Gernot Ruppelt highlights why culture and execution matter as much as fleet size in today’s tanker trade.
"The CEO’s role isn’t operational - it’s to set the long-term vision and take the risk buffer so others can take the micro bets that are needed to help grow the business,” Arun Narayanan explains why long-term thinking is essential to scaling sustainable energy.
"We’re hunting for the twelve entrepreneurs that will save the world - the 12 instigators,” Khosla Ventures' Rajesh Swaminathan highlights the firm’s disciplined focus on breakthrough founders and bold science.
"Changing the mindset from ‘more fertilizer equals more grain’ to ‘resilient soils equals profitability’ takes proof,” Arva Intelligence's Jay McEntire underlines how farmers themselves are the real heroes of regenerative agriculture.
"Our dream is to positively impact upon future generations, by being the leader in global efficiency in the agricultural sector, and, above all, to respect the planet,” Dr. Aurélio Pavinato outlines why soil health and circularity are central to SLC Agrícola's long-term growth.
